Featured Listing

AlphaMaven

Company Logo'

Venture Capital Featured Listing

BioHealth Capital Fund

Healing the World One Investment at a Time
Back

Venture Capital

Andrea Alms Video: Money In Motion 17

January 2022 - Venture Capital

posted by BioHealth Capital Fund
144


Video Transcript:

My name is Andrea ALMS.

I am biohealth investor, and financial manager and this is your Money in Motion

I was asked about our previous episode on stem cell therapy

·       *** remember …what does liposuction, skin, and COVID have in common…

·       ** Well, on this episode we explore NOT the therapy side

·       BUT, instead, what about all those tools and device that go into these cutting edge therapies…

What about tools vs the therapy market?

·       A quick thumb nail table shows that among some of the top therapy markets like

o  Stem cell

o  Cancer

o  Cardiovascular drug

o  That the tools market holds its own at market size of $48 billion in 2020

o  Estimated growth to a 227 billion global market size in 2026

o  With a compound average growth rate of 11.9 %

o   

What is the life science tools market?

o  Technological advancements in different life science tools are expected to enhance their adoption among prominent end users of the market, thereby leading to the market growth.

o  For instance, improvements in quantitative accuracy, Mass Spectrometry resolution and information sciences have enhanced the accuracy and utility of mass spectrometry-based methods in the field of proteomics.

 

o  Products such as Cell Culture Systems and 3D Cell Culture, Flow Cytometry, PCR and qPCR, Nucleic Acid Preparation, Nucleic Acid Microarray and Transfection Devices and Gene Delivery Technologies have witnessed substantial growth after the COVID-19 pandemic.

 

o  Novel research has suggested the use of a flow cytometry-based method for COVID-19 testing. Researchers have also used the technique to explore types of T cells involved in COVID-19 immune responses.

o   

o  RT-PCR assay is the most commonly used method for the detection of viral RNA in patient samples. Researchers have also developed specific assays to detect SARS-CoV-2.

o   

o  The Center for Disease Control (CDC) has developed a different test protocol by validation and comparison of several kits used in the extraction of nucleic acids. They also used alternative prime and probe sets to detect SARS-CoV-2 in clinical samples.

Competitive Landscape

·       The life science tools market is moderately competitive.

·       The market players adopted strategies such as product approval and launches, acquisition, partnerships, and agreements.

·       For instance, in 2019, Thermo Fisher Scientific Inc. and Owlstone Medical entered an agreement, under which both the companies will integrate Thermo’s Q Exactive GC Hybrid Quadrupole-Orbitrap Mass Spectrometer into Owlstone Medical’s Breath Biopsy platform.

·       Some of the market players include Becton, Dickinson and Company, Agilent Technologies, Illumina Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Merck KGaA, GE Healthcare, and Bruker QIAGEN. Corning Life Sciences

As you can see it is till a niche market with projected double digit growth rate…

Thank you

·       This is your money – your money in motion


ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.